Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Tina Guthrie"'
Autor:
Ian E. Krop, Warren P. Mason, Samuel C. Blackman, Tina Guthrie, Andrey Loboda, Cong Chen, Morris D. Groves, Steven J. Freedman, Maxine Giannotti, Jared Lunceford, Robert A. Beckman, Prakash Chinnaiyan, Santosh Kesari, Jeremy Hing, Patricia LoRusso, Tim Demuth, James Watters, Alexei A. Podtelezhnikov, Nicholas Butowski, Patrick Y. Wen
Publikováno v:
Journal of Clinical Oncology. 30:2307-2313
Purpose Aberrant Notch signaling has been implicated in the pathogenesis of many human cancers. MK-0752 is a potent, oral inhibitor of γ-secretase, an enzyme required for Notch pathway activation. Safety, maximum-tolerated dose, pharmacokinetics (PK
Autor:
Shirish M. Gadgeel, John Xu, Anthony F. Shields, Patricia LoRusso, Qi Liu, Tina Guthrie, Thomas A. Puchalski, Ulka N. Vaishampayan
Publikováno v:
Investigational new drugs. 29(6)
Background Cediranib is a highly potent vascular endothelial growth factor (VEGF) signaling inhibitor of all three VEGF receptors. This phase I, single-center, dose-finding study was designed primarily to investigate the safety and pharmacokinetics (
Autor:
Diane Durecki, David Craig, Tracy Bell, Shukmei Wong, Jessica Aldrich, Scott A. Boerner, Mary Jo Pilat, Sara M. Tolaney, Robert J. Kinders, Lihua Wang, Dongpo Cai, Adam Bowditch, John D. Carpten, Alice P. Chen, Tina Guthrie, Geoffrey I. Shapiro, Patricia LoRusso, Lance K. Heilbrun, Ralph E. Parchment
Publikováno v:
Cancer Research. 75:CT325-CT325
Background: The nuclear enzyme PARP is essential in recognition and repair of DNA damage. Preclinical evidence suggests that PARP inhibitors work as sensitizing agents for DNA-damaging agents such as irinotecan. Veliparib is an orally bioavailable PA
Autor:
J. R. Infante, C. Song, H. A. Burris, Jeannette Soria, C. Moldovan, J. Martini, Tina Guthrie, Patricia LoRusso, L. T. Nguyen
Publikováno v:
Journal of Clinical Oncology. 28:3070-3070
3070 Background: The PI3K pathway is frequently dysregulated in cancer cells and has been implicated as a mechanism of resistance to EGFR inhibitors. In preclinical xenograft models, the oral, sele...
Autor:
Howard A. Burris, Jean-Francois Martini, Christophe Massard, Ratislav Bahleda, Christian Scheffold, Jean-Charles Soria, Neil Faulkner, Jeffrey R. Infante, Johanna C. Bendell, Barbara Van Leeuwen, Patricia LoRusso, Tina Guthrie
Publikováno v:
Molecular Cancer Therapeutics. 8:C197-C197
Background: The PI3K pathway is frequently dysregulated in cancer cells and has been implicated as a mediator of resistance to EGFR inhibitors. In preclinical xenograft models, the oral selective Class I PI3K inhibitor XL147 augments the anti-tumor e
Autor:
D. D. Williams, Patricia LoRusso, Suzanne F. Jones, J. Sabry, J. P. Hodge, M. Bush, J. B. Orr, H. A. Burris, Tina Guthrie
Publikováno v:
Journal of Clinical Oncology. 22:2004-2004
2004 Background: The mitotic kinesin KSP plays an exclusive and essential role in assembly and function of the mitotic spindle. KSP represents a novel target for development of therapeutics against cancer. SB-715992 is a unique and selective inhibito